Immunity against the opportunistic fungal pathogen Pneumocystis

Medical Mycology

Volumn 43, Issue 1, 2005, Pages 1-19

  Steele, Chad ^a   Shellito, Judd E ^b   Kolls, Jay K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunosuppression; Pneumocystis; Pulmonary immunity

Indexed keywords

ANTIRETROVIRUS AGENT; BETA GLUCAN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MANNOSE RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AIDS RELATED COMPLEX; ASPERGILLUS FUMIGATUS; B LYMPHOCYTE; CANDIDA ALBICANS; CELLULAR IMMUNITY; CRYPTOCOCCUS NEOFORMANS; CYTOKINE PRODUCTION; DENDRITIC CELL; EPITHELIUM CELL; HISTOPLASMA CAPSULATUM; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; INCIDENCE; INFECTION RISK; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; PROTEIN BLOOD LEVEL; REVIEW; T LYMPHOCYTE;

ANIMALS; HUMANS; MICE; MICE, SCID; OPPORTUNISTIC INFECTIONS; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS;

FUNGI; PNEUMOCYSTIS; PNEUMOCYSTIS CARINII;

EID: 13244259242     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780400015360     Document Type: Review

References (198)

1. Chagas C. Nova tripanozomiaze humana. Mem Inst Oswaldo Cruz 1909; 1: 159-218.
2. Delanoe P. Sur les rapports des kystes des Carinii des poumon des rats avec le Trypanosoma lewisii. C R Acad Sci 1912; 155: 658.
3. Gajdusek DC. Pneumocystis carinii as the cause of human disease: historical perspective and magnitude of the problem: introductory remarks. Natl Cancer Inst Monogr 1976; 43: 1-11.
4. Edman JC, Kovacs JA, Masur H, et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988; 334: 519-522.
5. Stringer JR. Pneumocystis carinii: What is it, exactly. Clin Microbiol Rev 1996; 9: 489-498.
6. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002; 8: 891-896.
7. Van der Peer Y, Hendriks L, Goris A, et al. Evolution of basidiomyceteous yeasts as deduced from small ribosomal subunit RNA sequences. Syst Appl Microbiol 1992; 15: 250-258.
8. Pixley FJ, Wakefield AE, Banerji S, Hopkin JM. Mitochondrial gene sequences show fungal homology for Pneumocystis carinii. Mol Microbiol 1991; 5: 1347-1351.
9. Ypma-Wong MF, Fonzi WA, Sypherd PS. Fungus-specific translation elongation factor 3 gene present in Pneumocystis carinii. Infect Immun 1992; 60: 4140-4145.
10. Furlong ST, Samia JA, Rose RM, Fishman JA. Phytosterols are present in Pneumocystis carinii. Antimicrob Agents Chemother 1994; 38: 2534-2540.
11. Kottom TJ, Limper AH. Cell wall assembly by Pneumocystis carinii. Evidence for a unique gsc-1 subunit mediating beta-1,3-glucan deposition. J Biol Chem 2000; 275: 40628-40634.
12. Pifer LL, Hughes WT, Stagno D, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978; 61: 35-41.
13. Nevez G, Jounieaux V, Linas MD, et al. High frequency of Pneumocystis carinii sp.f. hominis colonization in HIV-negative patients. J Eukaryot Microbiol 1997; 44: 36S.
14. Sing A, Geiger AM, Hogardt M, Heesemann J. Pneumocystis carinii carriage among cystic fibrosis patients, as detected by nested PCR. J Clin Microbiol 2001; 39: 2717-2718.
15. Morris A, Beard CB, Huang L. Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect 2002; 4 95-103.
16. Peters SE, Wakefield AE, Sinckair K, et al. A search for Pneumocystis carinii in post-mortem lungs by DNA amplification. J Pathol 1992; 166: 195-198.
17. Wakefield AE, Pixley FJ, Banerjim S, et al. Detection of Pneumocystis carinii with DNA amplification. Lancet 1990; 336: 451-453.
18. Casanova-Cardiel L, Leibowitz MJ. Presence of Pneumocystis carinii DNA in pond water. J Eukaryot Microbiol 1997; 44: 28S.
19. Wakefield AE. DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f.sp. hominis in samples of air spora. J Clin Microbiol 1996; 34 1754-1759.
20. Wakefield AE. Detection of DNA sequences identical to Pneumocystis carinii in samples of ambient air. J Eukaryot Microbiol 1994; 41: 116S.
21. Navin TR, Rimland D, Lennox JL, et al. Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus. J Infect Dis 2000; 181: 158-164.
22. Singer C, Armstrong D, Rosen PP, Schottenfeld D. Pneumocystis carinii pneumonia: a cluster of eleven cases. Ann Intern Med 1975; 82: 772-777.
23. Chave JP, David S, Wauters JP, et al. Transmission of Pneumocystis carinii from AIDS patients to other immunosuppressed patients: a cluster of Pneumocystis carinii pneumonia in renal transplant patients. AIDS 1991; 5: 927-932.
24. Powles MA, McFadden DC, Pittarelli LA, Schmatz DM. Mouse model for Pneumocystis carinii pneumonia that uses natural transmission to initiate infection. Infect Immun 1992; 60: 1397-1400.
25. Vogel P, Miller CJ, Lowenstine LL, Lackner AA. Evidence of horizontal transmission of Pneumocystis carinii pneumonia in simian immunodeficiency virus-infected rhesus macaques. J Infect Dis 1993; 168: 836-843.
26. Gigliotti F, Harmsen AG, Wright TW. Characterization of transmission of Pneumocystis carinii f.sp. muris through immunocompetent BALB/c mice. Infect Immun 2003; 71: 3852-3856.
27. Bozzette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. New Engl J Med 1995; 332: 693-699.
28. Morris A, Wachter RM, Luce J, et al. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003; 17: 73-80.
29. Jain MK, Skiest DJ, Cloud JW, et al. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis 2003; 36: 1030-1038.
30. Pagano L, Fianchi L, Mele L, et al. Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol 2002; 117: 379-386.
31. Roblot F, Le Moal G, Godet C, et al. Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J Infect 2003; 47: 19-27.
32. Ibrahim-Granet O, Phillipe B, Boleti H, et al. Phagocytosis and intracellular fate of Aspergillus fumigatus conidia in alveolar macrophages. Infect Immun 2003; 71: 891-903.
33. He W, Casadevall A, Lee SC, Goldman DL. Phagocytic activity and monocyte chemotactic protein expression by pulmonary macrophages in persistent pulmonary cryptococcosis. Infect Immun 2003; 71: 930-936.
34. Brummer E, Stevens DA. Antifungal mechanisms of activated murine bronchoalveolar or peritoneal macrophages for Histoplasma capsulatum. Clin Exp Immunol 1996; 102: 65-70.
35. Masur H, Jones TC. The interaction in vitro of Pneumocystis carinii with macrophages and L-cells. J Exp Med 1978; 147: 157-170.
36. Von Behren LA, Pesanti EL. Uptake and degradation of Pneumocystis carinii by macrophages in vitro. Am Rev Respir Dis 1978; 118: 1051-1059.
37. Pottratz ST, Martin WJ. Mechanism of Pneumocystis carinii attachment to cultured rat alveolar macrophages. J Clin Invest 1990; 86: 1678-1683.
38. Ezekowitz RA, Williams DJ, Koziel H, et al. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature 1991; 351: 155-158.
39. O'Riordan DM, Standing JE, Limper AH. Pneumocystis carinii glycoprotein A binds macrophage mannose receptors. Infect Immun 1995; 63: 779-784.
40. Koziel H, Eichbaum Q, Kruskal BA, et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor down-regulation. J Clin Invest 1998; 102: 1332-1344.
41. Fraser IP, Takahashi K, Koziel H, et al. Pneumocystis carinii enhances soluble mannose receptor production by macrophages. Microbes Infect 2000; 2: 1305-1310.
42. Zhang J, Zhu J, Enrich A, et al. Pneumocystis activated human alveolar macrophages NF-kappaB signaling through mannose receptor. Infect Immun 2004; 72: 3147-3160.
43. Swain S, Lee SJ, Nussenzweig MC, Harmsen AG. Absence of the macrophage mannose receptor in mice does not increase susceptibility to Pneumocystis carinii infection in vivo. Infect Immun 2003; 71: 6213-6221.
44. Taylor MB, Phillips M, Easmon CS. Opsonophagocytosis of Pneumocystis carinii. J Med Microbiol 1992; 36: 223-228.
45. Kishor U, Madan T, Sarma PU, et al. Protective roles of pulmonary surfactant proteins, SP-A and SP-D, against lung allergy and infection caused by Aspergillus fumigatus. Immunobiol 2002; 205 610-618.
46. McCormack FX, Gibbons R, Ward SR, et al. Macrophage-independent fungicidal action of the pulmonary collectins. J Biol Chem 2003; 278: 36250-36256.
47. O'Riordan DM, Standing JE, Kwon KY, et al. Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest 1995; 95: 2699-2710.
48. McCormack FX, Festa AL, Andrews RP, et al. The carbohydrate recognition domain of surfactant protein A mediates binding to the major surface glycoprotein of Pneumocystis carinii. Biochemistry 1997; 36: 8092-8099.
49. Williams MD, Wright JR, March KL, Martin WJ. Human surfactant protein A enhances attachment of Pneumocystis carnii to rat alveolar macrophages. Am J Respir Cell Mol Biol 1996; 14: 232-238.
50. Koziel H, Phelps DS, Fishman JA, et al. Surfactant protein-A reduces binding and phagocytosis of Pneumocystis carinii by human alveolar macrophages in vitro. Am J Respir Cell Mol Biol 1998; 18: 834-843.
51. Yong S, Vuk-Pavlovic Z, Standing JE, et al. Surfactant protein D-mediated aggregation of Pneumocystis carinii impairs phagocytosis by alveolar macrophages. Infect Immun 2003; 71: 1662-1671.
52. Matsumoto Y, Matsuda S, Tegoshi T. Yeast glucan in the cyst wall of Pneumocystis carinii. J Protozool 1989; 36: 21S-22S.
53. De Stefano JA, Cushion MT, Puvanesarajah V, Walzer PD. Analysis of Pneumocystis carinii cyst wall. II. Sugar composition. J Protozool 1990; 37: 436-441.
54. De Stefano JA, Myers JD, DuPont D, et al. Cell wall antigens of Pneumocystis carinii trophozoites and cysts: purification and carbohydrate analysis of these glycoproteins. J Eukaryot Microbiol 1998; 45: 334-343.
55. Vassallo R, Standing J, Limper AH. Beta-glucan from Pneumocystis carinii stimulates TNF alpha release from alveolar macrophages. J Eukaryot Microbiol 1999; 46: 145S.
56. Lebron F, Vassalli P, Puri V, Limper AH. Pneumocystis carinii cell wall beta-glucans initiate macrophage inflammatory responses through NF-kappaB activation. J Biol Chem 2003; 278 25001-25008.
57. Vassallo R, Kottom TJ, Standing JE, Limper AH. Vitronectin and fibronectin function as glucan binding proteins augmenting macrophage responses to Pneumocystis carinii. Am J Resvir Cell Mol Biol 2001; 25: 203-211.
58. Steele C, Marrero L, Swain S, et al. Alveolar macrophage-mediated killing of Pneumocystis carinii f.sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor. J Exp Med 2003; 198: 1677-1688.
59. Taylor PR, Brown GD, Reid DM, et al. The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J Immunol 2002; 169: 3876-3882.
60. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004; 4: 1-23.
61. Hidalgo HA, Helmke RJ, German VF, Mangos JA. Pneumocystis carinii induces an oxidative burst in alveolar macrophages. Infect Immun 1992; 60: 1-7.
62. Laursen AL, Moller B, Rungby J, et al. Pneumocystis carinii-induced activation of the respiratory burst in human monocytes and macrophages. Clin Exp Immunol 1994; 98: 196-202.
63. Koziel H, Li X, Armstrong MY, Richards FF, Rose RM. Alveolar macrophages from human immunodeficiency virus-infected persons demonstrate impaired oxidative burst response to Pneumocystis carinii in vitro. Am J Respir Cell Mol Biol 2000; 23: 452-459.
64. Downing JF, Kachel DL, Pasula R, Martin WJ. Gamma interferon stimulates rat alveolar macrophages to kill Pneumocystis carinii by L-arginine- and tumor necrosis factor-dependent mechanisms. Infect Immun 1999; 67: 1347-1352.
65. Limper AH, Hoyte JS, Standing JE. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest 1997; 99: 2110-2117.
66. Rosenzweig SD, Holland SM. Phagocyte immunodeficiencies and their infections. J Allergy Clin Immunol 2004; 113: 620-626.
67. Fleury J, Escudier E, Pocholle MJ, et al. Cell population obtained by bronchoalveolar lavage in Pneumocystis carinii pneumonitis. Acta Cytol 1985; 29: 721-726.
68. Smith RL, el-Sadr WM, Lewis ML. Correlation of bronchoalveolar lavage cell populations with clinical severity of Pneumocystis carinii pneumonia. Chest 1998; 93: 60-64.
69. Jensen BN, Lisse IM, Gerstoft J, et al. Cellular profiles of bronchoalveolar lavage fluid of HIV-infected patients with pulmonary symptoms: relation to diagnosis and prognosis. AIDS 1991; 5: 527-533.
70. Sadaghdar H, Huand ZB, Eden E. Correlation of bronchoalveolar lavage findings to severity of Pneumocystis carinii pneumonia in AIDS. Evidence for the development of high-permeability pulmonary edema. Chest 1992; 102: 63-69.
71. Limper AH, Offord KP, Smith TF, Martin WJ. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989; 140: 1204-1209.
72. Benfield TL, Vestbo J, Junge J, et al. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995; 151: 1058-1062.
73. Benfield TL, Van Steenwijk R, Nielsen TL, et al. Interleukin-8 and eicosanoid production in the lung during moderate to severe Pneumocystis carinii pneumonia in AIDS: a role of interleukin-8 in the pathogenesis of P. carinii pneumonia. Respir Med 1995; 89: 285-290.
74. Fidel PL, Barousse M, Espinosa T, et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect Immun 2004; 72: 2936-2946.
75. Laursen AL, Obel N, Rungby J, Andersen PL. Phagocytosis and stimulation of the respiratory burst in neutrophils by Pneumocystis carinii. J Infect Dis 1993; 168: 1466-1471.
76. Laursen AL, Rungby J, Andersen PL. Decreased activation of the respiratory burst in neutrophils from AIDS patients with previous Pneumocystis carinii pneumonia. J Infect Dis 1995; 172: 497-505.
77. Stehle SE, Rogers RA, Harmsen AG, Ezekowitz RA. A soluble mannose receptor immunoadhesin enhances phagocytosis of Pneumocystis carinii by human polymorphonuclear leukocytes in vitro. Scand J Immunol 2000; 52: 131-137.
78. Morrison BE, Park SJ, Mooney SJ, Mehrad B. Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. J Clin Invest 2003; 112: 1862-1870.
79. Kawakami K, Koguchi Y, Qureshi MH, et al. NK cells eliminate Cryptococcus neoformans by potentiating the fungicidal activity of macrophages rather than by directly killing them upon stimulation with IL-12 and IL-18. Microbiol Immunol 2000; 44: 1043-1050.
80. Staugas RE, Beard LJ, Simmer K, Ferrante A. Hypogammaglobulinemia and depressed natural killer cell cytotoxicity in a patient with Pneumocystis carinii infection. Pediatr Infect Dis J 1998; 7: 724-728.
81. Bonagura VR, Cunningham-Rundles S, Edwards BL, et al. Common variable hypogammaglobulinemia, recurrent Pneumocystis carinii pneumonia on intravenous gamma-globulin therapy and natural killer cell deficiency. Clin Immunol Immunopathol 1989; 51: 216-231.
82. Bonagura VR, Cunningham-Rundles S, Schuval S. Dysfunction of natural killer cells in human immunodeficiency virus-infected children with or without Pneumocystis carinii pneumonia. J Pediatr 1992; 121: 195-201.
83. Hanano R, Reifenberg K, Kaufmann SH. Activated pulmonary macrophages are insufficient for resistance against Pneumocystis carinii. Infect Immun 1998; 66: 305-314.
84. Kolls JK, Habetz S, Shean MK, et al. IFN-gamma and CD8+ T cells restore host defenses against Pneumocystis carinii in mice depleted of CD4+ T cells. J Immunol 1999; 162: 2890-2894.
85. Garvy BA, Qureshi MH. Delayed inflammatory response to Pneumocystis carinii infection in neonatal mice is due to an inadequate lung environment. J Immunol 2000; 165: 6480-6486.
86. Zheng M, Shellito JE, Marrero L, et al. CD4(+) T-cell-independent vaccination against Pneumocystis carinii in mice. J Clin Invest 2001; 108: 1469-1474.
87. Vossen ME, Beckers BJ, Meuwissen JH, Stadhouders AM. Developmental biology of Pneumocystis carinii, and alternative view on the life cycle of the parasite. Z Parasitenkd 1978; 55: 101-118.
88. Yoshida Y, Matsumoto Y, Yamada M, et al. Pneumocystis carinii: electron microscopic investigation on the interaction of trophozoite and alveolar lining cell. Zentralbl Bakteriol Mikrobiol Hyg 1984; 256: 390-399.
89. Pesanti EL. Phospholipid profile of Pneumocystis carinii and its interaction with alveolar type II epithelial cells. Infect Immun 1987; 55: 736-741.
90. Steele C, Leigh JE, Swoboda RK, Fidel PL. Growth inhibition of Candida by human oral epithelial cells. J Infect Dis 2000; 182: 1479-1485.
91. Steele C, Ozenci H, Luo W, et al. Growth inhibition of Candida albicans by vaginal cells from naive mice. Med Mycol 1999; 37: 251-259.
92. Pottratz ST, Martin WJ. Role of fibronectin in Pneumocystis carinii attachment to cultured lung cells. J Clin Invest 1990; 85: 351-356.
93. Pottratz ST, Paulsrud J, Smith JS, Martin WJ. Pneumocystis carinii attachment to cultured lung cells by Pneumocystis gp 120, a fibronectin binding protein. J Clin Invest 1991; 88: 403-407.
94. Limper AH, Standing JE, Hoffman OA, et al. Vitronectin binds to Pneumocystis carinii and mediates organism attachment to cultured lung epithelial cells. Infect Immun 1993; 61: 4302-4309.
95. Pottratz ST, Weir AL, Wisniowski PE. Pneumocystis carinii attachment increases expression of fibronectin-binding integrins on cultured lung cells. Infect Immun 1994; 62: 5464-5469.
96. Pottratz ST, Weir AL. Gamma-interferon inhibits Pneumocystis carinii attachment to lung cells by decreasing expression of lung cell-surface integrins. Eur J Clin Invest 1997; 27: 17-22.
97. Kogan TV, Jadoun J, Mittelman L, et al. Involvement of secreted Aspergillus fumigatus proteases in disruption of the actin fiber cytoskeleton and loss of focal adhesion sites in infected A549 lung pneumocytes. J Infect Dis 2004; 189: 1965-1973.
98. Limper AH, Edens M, Anders RA, Leof EB. Pneumocystis carinii inhibits cyclin-dependent kinase activity in lung epithelial cells. J Clin Invest 1998; 101: 1148-1155.
99. Pottratz ST, Reese S, Sheldon JL. Pneumocystis carinii induces interleukin 6 production by an alveolar epithelial cell line. Eur J Clin Invest 1998; 28: 424-429.
100. Benfield TL, Lundgren B, Shelhamer JH, Lundgren JD. Pneumocystis carinii major surface glycoprotein induces interleukin-8 and monocyte chemoattractant protein-1 release from a human alveolar epithelial cell line. Eur J Clin Invest 1999; 29: 717-722.
101. Hahn PY, Evans SE, Kottom TJ, et al. Pneumocystis carinii cell wall beta-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J Biol Chem 2003; 278: 2043-2050.
102. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002; 15: 569-574.
103. Wallace JM, Hansen NI, Lavange L, et al. Respiratory disease trends in the Pulmonary Complications of HIV Infection Study cohort. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997; 155: 72-80.
104. Barton EG, Campbell WG. Pneumocystis carinii in lungs of rats treated with cortisone acetate. Ultrastructural observations relating to the life cycle. Am J Pathol 1969; 54: 209-236.
105. Chandler FW, Frenkel JK, Campbell WG. Pneumocystis pneumonia. Animal model: pneumocystis cartinii pneumonia in the immunosuppressed rat. Am J Pathol 1979; 95: 571-574.
106. Walzer PD, LaBine M, Redington TJ, Cushion MT. Lymphocyte changes during chronic administration of and withdrawal from corticosteroids: relation to Pneumocystis carinii pneumonia. J Immunol 1984; 133: 2502-2508.
107. Walzer PD, Schnelle V, Armstrong D, Rosen PP. Nude mouse: a new experimental model for Pneumocystis carinii infection. Science 1977; 197: 177-179.
108. Furuta T, Ueda K, Kyuma S, Fujiwara K. Effect of T-cell transfer on Pneumocystis carinii infection in nude mice. Jpn J Exp Med 1984; 54: 57-64.
109. Shellito J, Suzara VV, Blumenfeld W, et al. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest 1990; 85: 1686-1693.
110. Walzer PD, Kim CK, Linke M, et al. Outbreaks of Pneumocystis carinii pneumonia in colonies of immunodeficient mice. Infect Immun 1989; 57: 62-70.
111. Harmsen AG, Stankiewicz M. Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice. J Exp Med 1990; 172: 937-945.
112. Hanano R, Reifenberg K, Kaufmann SH. Naturally acquired Pneumocystis carinii pneumonia in gene disruption mutant mice: roles of distinct T-cell populations in infection. Infect Immun 1996; 64: 3201-3209.
113. Beck JM, Warnock ML, Curtis JL, et al. Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T lymphocytes. Am J Respir Cell Mol Biol 1991; 5: 186-197.
114. Roths JB, Sidman CL. Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice. J Clin Invest 1992; 90: 673-678.
115. Theus SA, Linke MJ, Andrews RP, Walzer PD. Proliferative and cytokine responses to a major surface glycoprotein of Pneumocystis carinii. Infect Immun 1993; 61: 4703-4709.
116. Theus SA, Andrews RP, Steele P, Walzer PD. Adoptive transfer of lymphocytes sensitized to the major surface glcoprotein of Pneumocystis carinii confers protection in the rat. J Clin Invest 1995; 95: 2587-2593.
117. Theus SA, Sullivan DW, Walzer PD, Smulian AG. Cellular responses to a 55-kilodalton recombinant Pneumocystis carinii antigen. Infect Immun 1994; 62: 3479-3484.
118. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-146.
119. Theus SA, Smulian AG, Sullivan DW, Walzer PD. Cytokine responses to the native and recombinant forms of the major surface glycoprotein of Pneumocystis carinii. Clin Exp Immunol 1997; 109 255-260.
120. Shellito JE, Tate C, Ruan S, Kolls J. Murine CD4+ T lymphocyte subsets and host defense against Pneumocystis carinii. J Infect Dis 2000; 181: 2011-2017.
121. Herrod HG, Valenski WR, Woods DR, Pifer LL. The in vitro response of human lymphocytes to Pneumocystis carinii antigen. J Immunol 1981; 126: 59-61.
122. Nakamoto A, Kitsukawa K. Human lymphocytes proliferative response and gamma interferon production to Pneumocystis carinii antigen in vitro. Kansenshogaku Zasshi 1992; 66: 1651-1659.
123. Forte M, Maartens G, Campbell F, et al. T-lymphocytes responses to Pneumocystis carinii in healthy and HIV-positive individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1992; 5 409-416.
124. Theus SA, Sawhney N, Smulian AG, Walzer PD. Proliferative and cytokine responses of human T lymphocytes isolated from human immunodeficiency virus-infected patients to the major surface glycoprotein of Pneumocystis carinii. J Infect Dis 1998; 177: 238-241.
125. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New Engl J Med 1998; 338: 853-860.
126. Thomas CF, Limper AH. Pneumocystis pneumonia. New Engl J Med 2004; 350: 2487-2498.
127. Mussini C, Pezzotti P, Antinori A, et al. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. J Infect Dis 2003; 36: 645-651.
128. Atzori C, Clerici M, Trabattoni D, et al. Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens. J Antimicrob Chemother 2003; 52: 276-281.
129. Pulvirenti J, Herrera P, Venkataraman P, Ahmed N. Pneumocystis carinii pneumonia in HIV-infected patients in the HAART era. AIDS Patient Care STDS 2003; 17: 261-265.
130. Hirsch HH, Kaufmann G, Sendi P. Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004; 38: 1159-1166.
131. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1: 107-115.
132. Barry SM, Lipman MC, Deery AR, et al. Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med 2002; 3: 207-211.
133. Wislez M, Bergot E, Antoine M, et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2001; 164: 847-851.
134. Dean GL, Williams DI, Churchill DR, Fisher MJ. Transient clinical deterioration in HIV patients with Pneumocystis carinii pneumonia after starting highly active antiretroviral therapy. Am J Respir Crit Care Med 2002; 165: 1670.
135. Wiley JA, Harmsen AG. CD40 ligand is required for resolution of Pneumocystis carinii pneumonia in mice. J Immunol 1995; 155: 3525-3529.
136. Beck JM, Newbury RL, Palmer BE, et al. Role of CD8+ lymphocytes in host defense against Pneumocystis carinii in mice. J Lab Clin Med 1996; 128: 477-487.
137. Steele C, Zheng M, Young E, et al. Increased host resistance against Pneumocystis carinii meumonia in gammadelta T-cell-deficient mice: protective role of gamma interferon and CD8(+) T cells. Infect Immun 2002; 70: 5208-5215.
138. McAllister F, Steele C, Zheng M, et al. T cytotoxic-1 CD8+ T cells are effector cells against Pneumocystis in mice. J Immunol 2004; 172: 1132-1138.
139. Zhou P, Friedag BL, Caldwell CC, Seder RA. Perforin is required for primary immunity to Histoplasma capsulatum. J Immunol 2001; 166: 1968-1974.
140. Ma LL, Spurrell JC, Wang JF, et al. CD8 T cell-mediated killing of Cryptococcus neoformans requires granulysin and is dependent on CD4 T cells and IL-15. J Immunol 2002; 169: 5787-5795.
141. Myers TA, Leigh JE, Arribas AR, et al. Immunohistochemical evaluation of T cells in oral lesions from human immunodeficiency virus-positive persons with oropharyngeal candidiasis. Infect Immun 2003; 71: 956-963.
142. Wright TW, Gigliotti F, Finkelstein JN, et al. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999; 104: 1307-1317.
143. Wright TW, Notter RH, Wang Z, Harmsen AG, Gigliotti F. Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia. Infect Immun 2001; 69: 758-764.
144. Wright TW, Pryhuber GS, Chess PR, et al. TNF receptor signaling contributes to chemokine secretion, inflammation, and respiratory deficits during Pneumocystis pneumonia. J Immunol 2004; 172: 2511-2521.
145. Kagi MK, Fierz W, Grob PJ, Russi EW. High proportion of gamma-delta T cell receptor positive T cells in bronchoalveolar lavage and peripheral blood of HIV-infected patients with Pneumocystis carinii pneumonias. Respiration 1993; 60: 170-177.
146. Agostini C, Zambello R, Trentin L, Semenzato G. T lymphocytes with gamma/delta T-cell receptors in patients with AIDS and Pneumocystis carinii pneumonia. AIDS 1995; 9: 203-204.
147. Hanano R, Kaufmann SH. Pneumocystis carinii pneumonia in mutant mice deficient in both TCRalphabeta and TCRgammadelta cells: cytokine and antibody responses. J Infect Dis 1999; 179: 455-459.
148. Hanano R, Kaufmann SH. Effect on parasite eradication of Pneumocystis carinii-specific antibodies produced in the presence or absence of CD4(+) alphabeta T lymphocytes. Eur J Immunol 1999; 29: 2464-2475.
149. Uezu K, Kawakami K, Miyagi K, et al. Accumulation of gamma delta T cells in the lungs and their regulatory roles in Th1 response and host defense against pulmonary infection with Cryptococcus neoformans. J Immunol 2004; 172: 7629-7634.
150. Wormley FL, Steele C, Wozniak KL, et al. Resistance of T-cell receptor delta-chain-deficient mice to experimental Candida albicans vaginitis. Infect Immun 2001; 69: 7162-7164.
151. Goldman DL, Khine H, Abadi J, et al. Serologic evidence for Cryptococcus infection in early childhood. Pediatrics 2001; 107: E66.
152. Furuta T, Fujiwara K, Yamanouchi K, Ueda K. Detection of antibodies to Pneumocystis carinii by enzyme-linked immunosorbent assay in experimentally infected mice. J Parasitol 1985; 71: 522-523.
153. Walzer PD, Rutledge ME. Humoral immunity in experimental Pneumocystis carinii infection. I. Serum and bronchial lavage fluid antibody responses in rats. J Lab Clin Med 1981; 97: 820-833.
154. Gigliotti F, Hughes WT. Passive immumoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest 1988; 81: 1666-1668.
155. Gigliotti F, Haidaris CG, Wright TW, Harmsen AG. Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect Immun 2002; 70: 1069-1074.
156. Harmsen AG, Chen W, Gigliotti F. Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice. Infect Immun 1995; 63: 2391-2395.
157. Garvy BA, Wiley JA, Gigliotti F, Harmsen AG. Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect Immun 1997; 65 6052-5056.
158. Huffnagle GB, Deepe GS. Innate and adaptive determinants of host susceptibility to medically important fungi. Curr Opin Microbiol 2003; 6: 344-350.
159. Harmsen AG, Stankiewicz M. T cells are not sufficient for resistance to Pneumocystis carinii pneumonia in mice. J Protozool 1991; 38: 44S-45S.
160. Marcotte H, Levesque D, Delanay K, et al. Pneumocystis carinii infection in transgenic B cell-deficient mice. J Infect Dis 1996; 173: 1034-1037.
161. Lund FE, Schuer K, Hollifield M, et al. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P. carinii-specific antibody. J Immunol 2003; 171: 1423-1430.
162. Wozniak KL, Leigh JE, Hager S, et al. A comprehensive study of Candida-specific antibodies in the saliva of human immunodeficiency virus-positive individuals with oropharyngeal candidiasis. J Infect Dis 2002; 185: 1269-1276.
163. Hofmann B, Odum N, Platz P, et al. Humoral responses to Pneumocystis carinii in patients with acquired immunodeficiency syndrome and in immunocompromised homosexual men. J Infect Dis 1995; 152: 838-840.
164. Pifer LL, Niell HB, Langdon SB, et al. Evidence for depressed humoral immunity to Pneumocystis cariniii in homosexual males, commercial plasma donors, and patients with acquired immunodeficiency syndrome. J Clin Microbiol 1987; 25: 991-995.
165. Rutstein RM. Predicting risk of Pneumocystis carinii pneumonai in human immunodeficiency virus-infected children. Am J Dis Child 1991; 145: 922-924.
166. Burns SM, Read JA, Yap PL, Brettle RP. Reduced concentrations of IgG antibodies to Pneumocystis carinii in HIV-infected patients during active Pneumocystis carinii infection and the possibility of passive immunisation. J Infect 1990; 20: 33-39.
167. Elvin K, Bjorkman A, Heurlin N, et al. Seroreactivity to Pneumocystis carinii in patients with AIDS versus other immunosuppressed patients. Scand J Infect Dis 1994; 26: 33-40.
168. Laursen AL, Andersen PL. Low levels of IgG antibodies against Pneumocystis carinii among HIV-infected patients. Scand J Infect Dis 1998; 30: 495-499.
169. Lundgren B, Lundgren JD, Nielsen T, et al. Antibody responses to a major Pneumocystis carinii antigen in human immunodeficiency virus-infected patients with and without P. carinii pneumonia. J Infect Dis 1992; 165: 1151-1155.
170. Buhl L, Settnes OP, Andersen PL. Antibodies to Pneumocystis carinii in Danish blood donors and AIDS patients with or without Pneumocystis carinii pneumonia. APMIS 1993; 101 707-710.
171. Bishop LR, Kovacs JA. Quantitation of anti-Pneumocystis jiroveci antibodies in healthy persons and immunocompromised patients. J Infect Dis 2003; 187: 1844-1848.
172. Daly KR, Koch J, Levin L, Walzer PD. Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci. Emerg Infect Dis 2004; 10: 848-854.
173. el-Sibae MM, Farrag AM. The level of IgG and IgM in Pneumocystis carinii infection. J Egypt Soc Parasitol 1989; 19: 635-639.
174. Laursen AL, Jensen BN, Andersen PL. Local antibodies against Pneumocystis carinii in bronchalveolar lavage fluid. Eur Respir J 1994; 7: 679-685.
175. Milledge J, Kakakios A, Gillis J, Fitzgerald D. Pneumocystis carinii pneumonia as a presenting feature of X-linked hyper-IgM syndrome. J Paediatr Child Health 2003; 39: 704-706.
176. el-Sibae MM, el-Helaly SM, Aly AG, Faris L. Correlation between the level of IgA and Pneumocystis carinii infection. J Egypt Soc Parasitol 1991; 21: 771-777.
177. Jalil A, Moja P, Lambert C, et al. Decreased production of local immunoglobulin A to Pneumocystis carinii in bronchoalveolar lavage fluid from human immunodeficiency virus-positive patients. Infect Immun 2000; 68: 1054-1060.
178. Ellaurie M, Rubinstein A, Rosenstreich DL. IgE levels in pediatric HIV-1 infection. Ann Allergy Asthma Immunol 1995; 75 332-336.
179. Ishimine T, Kawakami K, Nakamoto A, Saito A. Analysis of cellular response and gamma interferon synthesis in bronchoalveolar lavage fluid and lung homogenate of mice infected with Pneumocystis carinii. Microbiol Immunol 1995; 39: 49-58.
180. Pesanti EL. Interaction of cytokines and alveolar cells with Pneumocystis carinii in vitro. J Infect Dis 1991; 163: 611-616.
181. Shear HL, Valladares G, Narachi MA. Enhanced treatment of Pneumocystis carinii pneumonia in rats with interferon-gamma and reduced doses of trimethoprim/sulfamethoxazole. J Acquir Immune Def Syndr 1990; 3: 943-948.
182. Beck JM, Liggit HD, Brunette EN, et al. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of interferon-gamma. Infect Immun 1991; 59: 3859-3862.
183. Garvy BA, Gigliotti F, Harmsen AG. Neutralization of interferon-gamma exacerbates Pneumocystis-driven interstitial pneumonitis after bone marrow transplantation in mice. J Clin Invest 1997; 99: 1637-1644.
184. Garvy BA, Ezekowitz RA, Harmsen AG. Role of gamma interferon in the host immune and inflammatory responses to Pneumocystis carinii infection. Infect Immun 1997; 65: 373-379.
185. Herring AC, Huffnagle GB. In: S. Kaufmann HE (ed.). Immunology of Infectious Diseases. Washington DC: ASM Press, 2002.
186. Tamburrini E, De Luca A, Ventura G, et al. Pneumocystis carinii stimulates in vitro production of tumor necrosis factor-alpha by human macrophages. Med Microbiol Immunol 1991; 180: 15-20.
187. Hoffman OA, Standing JE, Limper AH. Pneumocystis carinii stimulates tumor necrosis factor-alpha release from alveolar macrophages through a beta-glucan-mediated mechanism. J Immunol 1993; 150: 3932-3940.
188. Kandil O, Fishman JA, Koziel H, et al. Human immunodeficiency virus type 1 infection of human macrophages modulates the cytokine response to Pneumocystis carinii. Infect Immun 1994; 62: 644-650.
189. Kolls JK, Beck JM, Nelson S, et al. Alveolar macrophage release of tumor necrosis factor during murine Pneumocystis carinii pneumonia. Am J Respir Cell Mol Biol 1993; 8: 370-376.
190. Kolls JK, Lei D, Vazquez C, et al. Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor. Am J Respir Cell Mol Biol 1997; 16 112-118.
191. Chen W, Havell EA, Harmsen A. Importance of endogenous tumor necrosis factor-alpha and gamma interferon in host resistance against Pneumocystis carinii infection. Infect Immun 1992; 60: 1279-1284.
192. Rudmann DG, Preston AM, Moore MW, Beck JM. Susceptibility to Pneumocystis carinii in mice is dependent on simultaneous deletion of IFN-gamma and type 1 and 2 TNF receptor genes. J Immunol 1998; 161: 360-366.
193. Chen W, Havell EA, Moldawer LL, et al. Interleukin 1: an important mediator of host resistance against Pneumocystis carinii. J Exp Med 1992; 176: 713-718.
194. Chen W, Havell EA, Gigliotti F, Harmsen A. Interleukin-6 production in a murine model of Pneumocystis carinii pneumonia: relation to resistance and inflammatory response. Infect Immun 1993; 61: 97-102.
195. Ruan S, Tate C, Lee JJ, et al. Local delivery of the viral interleukin-10 Gene suppresses tissue inflammation in murine Pneumocystis carinii infection. Infect Immun 2002; 70: 6107-6113.
196. Qureshi MH, Harmsen AG, Garvy BA. IL-10 modulates host responses and lung damage induced by Pneumocystis carinii infection. J Immunol 2003; 170: 1002-1009.
197. Mandujano JF, D'Souza NB, Nelson S, et al. Granulocyte-macrophage colony stimulating factor and Pneumocystis carinii pneumonia in mice. Am J Respir Crit Care Med 1995; 151: 1233-1238.
198. Paine R, Preston AM, Wilcoxen S, et al. Granulocyte-macrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice. J Immunol 2000; 164: 2602-2609.